Department of Medical Oncology, HCG Manavata Cancer Centre, Nashik - 422011, Maharashtra, India.
Radiation Oncology, HCG Manavata Cancer Centre, Nashik - 422011, Maharashtra, India.
Cancer Treat Res Commun. 2021;26:100280. doi: 10.1016/j.ctarc.2020.100280. Epub 2020 Dec 11.
Alopecia is one of the most common and afflicting side effects associated with chemotherapy treatments. Scalp-cooling devices were introduced to reduce hair loss and improve the hair volume recovery in patients undergoing chemotherapy.
This is a single center, prospective observational study conducted from 01 February 2019 to 31 January 2020, in patients undergoing chemotherapy for various cancers. The extent of alopecia was assessed by two independent clinicians by reviewing the photographs taken at baseline, during each session, and 4 weeks from the last scalp cooling session.
A total of 100 patients (female: 94 and male: 6) were enrolled in the study, with a mean age of 53.5 years. Of 100 patients, 40 received anthracycline based chemotherapy, 45 received taxane based chemotherapy, 9 received both, and 6 received other chemotherapeutic agents. By the end of the study, 31 patients experienced grade 0-1 alopecia and 69 patients had grade 2 alopecia. On multivariate analysis, chemotherapeutic agent was found to be an independent factor for delaying the onset of Grade 2 alopecia (anthracycline vs taxanes (OR: 0.71; 95% CI (0.51-0.92); P ≤ 0.04)The most common adverse events reported during the scalp cooling sessions were chills (7%), and chills with headaches (6%). Scalp metastasis and scalp cooling discontinuation rates were observed to be very rare. No serious adverse events related to device were observed.
Scalp cooling was observed to be more effective in reducing chemotherapy-induced alopecia in patients treated with taxane-based chemotherapy over anthracyclines. Scalp cooling sessions were well tolerated. Scalp metastasis and scalp cooling discontinuation was observed to be very rare.
脱发是化疗治疗中最常见和最令人困扰的副作用之一。头皮冷却设备的引入旨在减少脱发并改善接受化疗的患者的头发体积恢复。
这是一项于 2019 年 2 月 1 日至 2020 年 1 月 31 日在接受各种癌症化疗的患者中进行的单中心前瞻性观察研究。通过查看基线、每次治疗期间以及最后一次头皮冷却治疗后 4 周拍摄的照片，由两位独立的临床医生评估脱发程度。
共有 100 名患者（女性 94 名，男性 6 名）入组该研究，平均年龄为 53.5 岁。在 100 名患者中，40 名接受了基于蒽环类药物的化疗，45 名接受了基于紫杉烷的化疗，9 名同时接受了两种化疗，6 名接受了其他化疗药物。研究结束时，31 名患者出现 0-1 级脱发，69 名患者出现 2 级脱发。多变量分析发现，化疗药物是延迟 2 级脱发发生的独立因素（蒽环类药物与紫杉烷类药物（OR：0.71；95%CI（0.51-0.92）；P≤0.04）。头皮冷却过程中报告的最常见不良事件是寒战（7%）和伴有头痛的寒战（6%）。头皮转移和头皮冷却停止的发生率很低。未观察到与设备相关的严重不良事件。
与蒽环类药物相比，头皮冷却在减少接受基于紫杉烷类药物的化疗患者的化疗诱导性脱发方面更为有效。头皮冷却治疗耐受性良好。头皮转移和头皮冷却停止的发生率非常低。
